Erratum to: Clinical audit of POM-V / POM prescriptions by remote consultation via a veterinary video telemedicine smartphone application




Dr Sheila Mary Smith BVMS MRCVS1
 
Dr Tamsin Day BVetMed MRCVS1

Dr Samantha Georgina Webster BVetMed MRCVS1

Sam Davies BSc1

Dr Trevor Peter Hardcastle BSc MSc PhD1

Dr Adele Williams BVSc MRCVS DipECEIM PhD1*


 

1Vet-AI, Ebble House, Odstock, Salisbury, England, SP5 4JB

*Corresponding Author (adele.williams@vet-ai.com)










Vol 7, Issue 2 (2022)

Erratum published: 20 Jun 2022

Original paper published: 08 Jun 2022

The original article was published in Veterinary Evidence Vol 7, Issue 2 (2022):  10.18849/VE.V7I2.553

DOI: 10.18849/VE.V7I2.627







      

ERRATUM

      

Unfortunately the original version of the article had the following two errors.

Within the Results section after Figure 6 under the sub-heading Complete / expected response to treatment was changed from:

Complete / expected response to treatment

60.3% (2,135/3,541) of remote consultations which were prescribed a POM-V / POM product resulted in the outcome complete or expected response to treatment.

	8% (1,197 /3,541) complete response / resolutions of clinical signs after follow-up appointment or email
	5% (938/3,541) expected response to treatment (complete resolution of signs not expected in these cases most requiring chronic ongoing medication e.g., non-steroidal anti-inflammatory drugs (NSAID) for chronic osteoarthritis, or anti-pruritic for atopic dermatitis)


Of the consults where the outcome was known (when the outcome category ‘no treatment outcome available’ was removed) 89.0% (2,135/2,399) of all treatment outcomes were complete / expected response to treatment.

To:

Complete / expected response to treatment 

60.3% (2,135/3,541) of remote consultations which were prescribed a POM-V / POM product resulted in the outcome complete or expected response to treatment.

	33.8% (1,197 /3,541) complete response / resolutions of clinical signs after follow-up appointment or email
	26.5% (938/3,541) expected response to treatment (complete resolution of signs not expected in these cases most requiring chronic ongoing medication e.g., non-steroidal anti-inflammatory drugs (NSAID) for chronic osteoarthritis, or anti-pruritic for atopic dermatitis)


Of the consults where the outcome was known (when the outcome category ‘no treatment outcome available’ was removed) 89.0% (2,135/2,399) of all treatment outcomes were complete / expected response to treatment.

This error was in both the HTML and PDF versions. This has now been updated in both the HTML and PDF versions.

 

Within the Results section after Figure 6 under the sub-heading No treatment outcome available was changed from:

No treatment outcome available

Of the 3,541 consultations in which a prescription was purchased, 32.3% (1,142/3,541), had no treatment outcome available for the following reasons:

	4% (1,078/3,541) No feedback received (lost to follow-up despite multiple attempts)
	8% (64/3,541) patients were not administered prescribed medication for reasons including:
	postal delay / out of stock (those cases were referred into practice)
	condition deteriorated prior to commencement of treatment and were referred into practice
	symptoms resolved before medication was administered
	order cancelled by owner





To:

No treatment outcome available

Of the 3,541 consultations in which a prescription was purchased, 32.3% (1,142/3,541), had no treatment outcome available for the following reasons:

	30.4% (1,078/3,541) No feedback received (lost to follow-up despite multiple attempts)
	1.8% (64/3,541) patients were not administered prescribed medication for reasons including:
	postal delay / out of stock (those cases were referred into practice)
	condition deteriorated prior to commencement of treatment and were referred into practice
	symptoms resolved before medication was administered
	order cancelled by owner





This error was in both the HTML and PDF versions. This has now been updated in both the HTML and PDF versions.
 







  
Intellectual Property Rights

    Authors of Knowledge Summaries submitted to RCVS Knowledge for publication will retain copyright in their work, and will be required to grant to RCVS Knowledge a non-exclusive licence of the rights of copyright in the materials including but not limited to the right to publish, re-publish, transmit, sell, distribute and otherwise use the materials in all languages and all media throughout the world, and to licence or permit others to do so.